Human prolactin antagonist-angiogenesis inhibitor fusion proteins
CA 2487291 A1 · Owner: Ghc Research Development Corporation · Inventors: Chen, Wen Yuan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel fusion protein, comprising a receptor-antagonizing domain and an angiogensis inhibiting domain, characterized for example, by its ability to , block apoptosis and/or inhibit endocrine response is useful in treating , cancer. For example a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 2, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.